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OBJECTIVES We sought to determine the predictors of heart failure (HF) development in long-term
survivors of myocardial infarction (MI).
BACKGROUND Modern strategies of acute MI care have resulted in an increasing proportion of survivors at
heightened risk of future non-fatal events, including HF.
METHODS We assessed the risk of developing HF in 3,860 stable MI patients without a previous history
of HF, who were enrolled in the Cholesterol And Recurrent Events (CARE) trial a median
of 10 months post MI. Baseline characteristics of patients who did or did not develop HF
during the five years of observation were assessed.
RESULTS A total of 243 patients (6.3%) developed HF in a linear pattern at a rate of 1.3%/year. Heart
failure development markedly increased the risk of death (hazard ratio 10.2, 95% confidence
interval 7.7 to 13.5). Fifty-seven patients (23.5%) who developed HF had a recurrent MI
between enrollment and the onset of HF, increasing the risk fivefold. The most important
predictors of HF were age and left ventricular ejection fraction. Other predictors included
diabetes, history of hypertension, previous MI, and baseline heart rate. Moderate exercise
three or more times per week was independently associated with a 30% lower risk of HF.
CONCLUSIONS Heart failure post MI occurs in a time-dependent fashion, which is usually not a direct
consequence of a detectable interim MI. Patients who experience late-onset HF have a
10-fold increased risk of death compared with other MI survivors. Baseline characteristics can
risk stratify patients at high risk of subsequent HF. (J Am Coll Cardiol 2003;42:1446–53)
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Myocardial infarctions (MIs) are associated with increased
short- and long-term mortality (1). This risk of death in
survivors of MI is not uniform, however. Multiple prognos-
tic factors, including the patient’s baseline characteristics,
the extent and complications of MI, and the use of medi-
cations and procedures, have been shown to impact the risk
of death (2,3). Survivors of MI are also at heightened risk of
developing major non-fatal cardiovascular events, including
recurrent MI, arrhythmia, stroke, and heart failure (HF)
(1,4–6). The risk of experiencing these important cardio-
vascular events also varies considerably across the spectrum
of MI survivors. The development of HF post MI is
particularly serious because patients manifesting HF have a
several-fold increase in the risk of death when compared
with other MI survivors (1,7). A better understanding of the
factors involved in the eventual development of HF in
long-term MI survivors will better identify high-risk pa-
tients more likely to benefit from implementation of more
intensive preventive measures and generate potential mech-
anistic information. The objective of this analysis was to
provide a quantitative evaluation of the factors that predict
the development of HF in stable patients far removed from
their MIs.
METHODS
The Cholesterol And Recurrent Events (CARE) trial en-
rolled 4,159 patients who survived MI within the preceding
3 to 20 months (mean 10), with a total cholesterol level
240 mg/dl, a low-density lipoprotein level between 115
and 174 mg/dl, and a fasting triglyceride level 350 mg/dl.
The study organization, recruitment of patients, random-
ization, and follow-up in the CARE trial have been de-
scribed in detail elsewhere (8,9). Briefly, patients were
randomized to conventional therapy plus either 40 mg/day
pravastatin or placebo. Eligible patients were required to
have a fasting glucose 220 mg/dl. The left ventricular
ejection fraction (LVEF) was assessed in all patients, and
those with LVEF 25% were excluded. Patients with
symptomatic HF at the time of randomization, despite
medical therapy, were excluded. Other exclusion criteria
included excessive ethanol intake, defined as 3 drinks per
day, severe valvular disease, renal disease (creatinine 1.5
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times the upper limit of normal or urine protein 2),
untreated endocrine disorders, significant gastrointestinal
disease or surgery that may interfere with drug absorption,
hepatobiliary disease, malignancy or a medical condition
thought to limit survival, or a history of immune disorders.
Recruitment for CARE occurred in 80 centers (67 in the
U.S. and 13 in Canada) between December 4, 1989, and
December 31, 1991, with a designed follow-up of five years.
The institutional review boards at each participating center
approved the CARE protocol, and all patients provided
informed consent.
The 299 CARE patients with a previous history of HF
were excluded from this analysis to create a cohort of 3,860
patients without current or past symptomatic HF. The risk
and timing of developing HF in this stable, post-MI
population are the subjects of this study.
After randomization, visits to the clinic occurred quar-
terly. The development of HF was prospectively defined as
hospital admission for the management of HF. To confirm
the diagnosis of HF, attempts were made to obtain hospital
records, consultation notes, discharge summaries, and per-
tinent laboratory data. A secondary outcome was all-cause
mortality or hospitalization for HF. Patients who performed
at least moderate physical activity (e.g., brisk walking, riding
a stationary bicycle, or moderate gardening or housework)
three or more times per week at baseline were grouped into
the moderate exercise category. The remaining patients who
did not perform this minimum amount of physical activity
comprised the reference group.
Statistical analysis. The comparability of baseline charac-
teristics in the patients who were hospitalized for HF and
those without HF was assessed using the chi-square test for
categorical variables and the standard z test for continuous
variables. All hypothesis testing and all risk reductions with
confidence intervals were assessed using the Cox propor-
tional hazards model (10). Kaplan-Meier survival curves for
the patients who developed HF and those who did not were
calculated (11).
The attributable risk of hypertension, diabetes, and exer-
cise was calculated using the difference between the cumu-
lative incidence rate of HF in the exposed group from the
cumulative incidence rate of HF in the non-exposed group
(12,13). This difference was converted to a percentile,
reflecting the absolute effect of the exposure to the putative
risk factor on the development of HF. Variables significant
on univariate analyses were candidate variables for the
multivariate model. Cox proportional hazards modeling was
used to determine multivariate baseline predictors of HF
development. Predictors in each analysis were tested using
the likelihood ratio chi-square test. Hazard ratios (HRs)
were calculated with 95% confidence intervals (CIs) for
significant variables. The final model included those co-
variates that remained significant in predicting HF as well as
HF and death (using a p value 0.01). Co-linearity was
assessed by the evaluation of correlation coefficients, and the
presence of effect modification was examined using interac-
tion terms.
Risk profiles were created empirically based on the multi-
variate predictors of HF post MI. Patients were characterized
into low, medium, and high risk of HF based on the presence
or absence of baseline predictors. The subsequent development
of HF was assessed in these three groups.
RESULTS
Timing of events. Of 3,860 patients without a previous
history of HF, a total of 243 (6.3%) were hospitalized for
the management of HF during a median follow-up of five
years. The cumulative incidence of HF increased in a
time-dependent manner at a rate of1.3% per year (Fig. 1).
The cumulative incidence of death or HF development was
also linear, with 2.2% of patients either dying or devel-
oping HF by one year after randomization and 14% of
patients dying or developing HF by five years.
Of the 243 patients who developed HF, 57 (23.5%) had
a recurrent MI. Among these 57 patients, 34 experienced a
recurrent MI at a median of 247 days before the hospital-
ization for HF, and in the remainder of the patients with
recurrent MIs (n  23), HF occurred simultaneously.
Among the 3,617 patients who did not develop HF,
recurrent MI occurred significantly less frequently (7.3% vs.
23.5%, p  0.0001).
As a consequence of developing HF, the risk of death was
Figure 1. Cumulative incidence of hospitalization for heart failure (HF)
and death or hospitalization for HF in patients enrolled in the CARE trial
without a previous history of HF. The upper line represents the cumulative
incidence of all-cause mortality or hospitalization for HF, and the lower
line represents only HF hospitalizations.
Abbreviations and Acronyms
CARE  Cholesterol And Recurrent Events trial
HF  heart failure
HR  hazard ratio
LVEF  left ventricular ejection fraction
MI  myocardial infarction
SAVE  Survival And Ventricular Enlargement trial
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much greater than in those without HF (HR 10.2, CI 7.7 to
13.5; p  0.0001). Sixty-eight (28%) of 243 patients died at
a mean of 43 16 months after HF development. This rate
is significantly different from the 252 (7%) of 3,617 patients
without HF who died during follow-up (p  0.0001).
Patient characteristics. The baseline characteristics of pa-
tients with and without HF development during follow-up
are summarized in Table 1. Patients developing HF were
older than patients without HF (p  0.0001). The devel-
opment of HF occurred progressively more commonly with
increasing age (Fig. 2). Heart failure occurred in 57 (13%) of
432 patients over 70 years old and in 186 (5.4%) of 3428
patients younger than 70 years old (p  0.001). Only 1.7%
of patients under the age of 50 years developed HF during
the five-year follow-up. Patients with a lower baseline left
ventricular ejection fraction were more likely to develop HF
(Fig. 3).
The most common co-morbid illnesses present in pa-
tients developing HF were hypertension and diabetes.
Among the 243 patients who developed HF, 138 (57%) had
a history of hypertension, with an attributable risk of 16%.
A total of 52 (21.4%) of the 243 patients had a history of
diabetes, with an attributable risk of 9%. Patients who
developed HF were also more likely to be current smokers at
the time of randomization to the CARE trial. A history of
MI before the index MI was more common in patients who
developed HF (28.0% vs. 13.2%, p  0.001).
The patients who developed HF had higher systolic and
diastolic blood pressures and higher heart rates. Coronary
artery bypass grafting was previously performed more com-
monly in patients who developed HF, whereas previous
angioplasty was more prevalent in patients who did not
develop HF. Patients who exercised moderately at least
three times weekly (n  2,263) were also less likely to
Table 1. Baseline Characteristics of Patients With and Without the Development of Heart
Failure in Long-Term Survivors of MI
Characteristics
No Heart Failure
Development
(n  3,617 [93.7%])
Heart Failure
Development
(n  243 [6.3%]) p Value
Demographics
Age (yrs) 58.0  9.3 62.3  7.2  0.001
Female (number) 479 (13.2%) 42 (17.3%) 0.081
Race (non-white) 257 (7.1%) 31 (12.8%) 0.002
Body mass index (kg/m2) 27.6  6.4 28.8  4.9 0.004
Risk factors and behavior
Diabetes 461 (12.8%) 52 (21.4%)  0.001
History of hypertension 1,479 (40.9%) 138 (56.8%)  0.001
Current smoker 580 (16.0%) 51 (21.0%) 0.048
Moderate exercise (3 times/week) 2,141 (59.2%) 122 (50.2%)  0.001
Cardiovascular history
Previous MI 479 (13.2%) 68 (28.0%)  0.001
Previous CABG 881 (24.4%) 87 (35.8%)  0.001
Previous angioplasty 1,245 (34.4%) 65 (26.8%) 0.014
Previous CABG or angioplasty 1,950 (53.9%) 135 (55.6%) 0.642
History of atrial fibrillation/flutter 44 (1.2%) 5 (2.1%) 0.233
Presenting characteristics
Q-wave MI 2,198 (86.3%) 151 (83.4%) 0.684
Thrombolytic treatment 1,540 (42.6%) 94 (38.7%) 0.230
Peak creatinine kinase 1,685  1,586 1,698  1,441 0.901
LVEF (%) 54.1  11.6 48.2  13  0.001
Systolic blood pressure (mm Hg) 128.5  18 133.6  20  0.001
Diastolic blood pressure (mm Hg) 78.6  10 80.1  12 0.026
Lipid profile
Total cholesterol (mg/dl) 208.7  17 208  17 0.53
LDL cholesterol (mg/dl) 138.7  15 138.4  14 0.76
HDL cholesterol (mg/dl) 38.9  9 38.4  8 0.40
Triglycerides (mg/dl) 155.7  61 155.5  56 0.96
Medications at presentation
ACE inhibitors 411 (11.4%) 47 (19.3%)  0.001
Beta-blockers 1,474 (40.8%) 89 (36.6%) 0.224
Aspirin 3,054 (84.4%) 189 (77.8%) 0.009
Nitrates 1,108 (30.6%) 120 (49.4%)  0.001
Diuretics 278 (7.7%) 56 (23.1%)  0.001
Calcium-channel blockers 1,430 (39.5%) 107 (44.0%) 0.176
Digoxin 194 (5.4%) 33 (13.6%)  0.001
Data are presented as the mean value  SD or number (%) of subjects.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass grafting; HDL  high-density lipoprotein; LDL
 low-density lipoprotein; LVEF  left ventricular ejection fraction; MI  myocardial infarction.
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develop HF than those not exercising regularly at baseline
(HR 0.69, 95% CI 0.54 to 0.89; p  0.0001). The
characteristics of the index MI were not associated with
increased HF development, with no differences in the
percentage of patients with Q-wave MI or those who
received thrombolytic therapy. The peak cardiac enzyme
levels and baseline lipid profile were also not different
between the two groups.
At the time of randomization, the patients who devel-
oped HF were more often taking angiotensin-converting
enzyme inhibitors, nitrates, diuretics, and digoxin and were
taking beta-blockers less often.
Multivariate predictors of HF development and outcomes.
Multivariate analysis identified seven independent predic-
tors of HF in stable survivors of MI without a previous
history of HF (Table 2). Age (p  0.001) was the most
powerful predictor of HF development, with a 7% higher
risk of HF for every one-year increase in age. Left ventric-
ular ejection fraction was the second most significant pre-
dictor of HF development post MI, with a 4% increase in
the risk of HF for every 1% decrease in baseline LVEF (p
0.001). Patients 60 years old had a very low HF rate,
unless the LVEF was 35% (Fig. 4A).
The only finding on physical examination that was
independently associated with the development of HF was
a higher baseline heart rate (p  0.001). Hypertension and
MI before the index MI were also important predictors of
HF development. Regular exercise at baseline was inversely
related to the risk of HF development. Patients who
exercised at least three times weekly at baseline exhibited a
lower risk of developing HF than patients who did not
exercise as frequently. Patients with diabetes had a 42%
increase in the risk of HF development, as compared with
non-diabetics. After adjusting for confounding factors, the
Killip class at the time of the index MI and body mass index
(HR 1.01, 95% CI 1.00 to 1.02; p  0.07) no longer
remained significant. Assignment to pravastatin, compared
with placebo, did not decrease the rate of HF development
(6.1% vs. 6.9%, p  0.31).
The risk of developing HF after surviving MI increased
with a higher number of risk factors. Based on the final
multivariate model, the most important predictors of HF
were age and LVEF. Patients can be grouped into high-,
intermediate-, and low-risk groups (Table 3) according to
the baseline characteristics predictive of HF. The high-risk
group was defined as age60 years, LVEF50%, a history
of hypertension, and diabetes. The intermediate-risk group
could have LVEF 50% if they had other predictive risk
factors. The patients who did not meet criteria for the
high-risk and intermediate-risk groups were considered as
the low-risk group. Using the low-risk patients as the
reference group, the risk of HF development was fourfold
higher in the intermediate group and 15-fold higher in the
high-risk group. These two groups were also at a signifi-
cantly higher risk of HF and death compared with the
low-risk group.
A total of 311 patients developed recurrent MI during
follow-up. The occurrence of recurrent MI increased the
risk of HF development dramatically (HR 4.91, 95% CI
3.45 to 6.97; p  0.001). Recurrent MI significantly
increased the risk of HF development, irrespective of the
baseline risk profile of the patient.
DISCUSSION
Over the past few decades, with advances in the manage-
ment of acute MI, there has been a decline of over 40% in
all-cause mortality during the acute phase of MI (14). These
successes have resulted in a larger pool of infarct survivors
who remain at risk of other significant cardiovascular events,
such as arrhythmias, recurrent MI, stroke, and the develop-
ment of HF. Subsequent to increased survival, the risk of
HF following MI has not decreased (14). Based on the
results of the Multicenter Automatic Defibrillator Implan-
tation Trial (MADIT II) (15), the number of patients with
coronary artery disease and LVEF 30% who will receive
an implantable defibrillator will likely increase, resulting in
an even larger pool of patients surviving MI who will be at
risk of subsequent HF development. As such, HF after MI
remains a major concern. Patients developing HF during
hospitalization for MI have a much greater in-hospital
mortality rate. Little is known, however, about the predic-
Figure 2. The impact of age on the development of heart failure after an
myocardial infarction in the CARE trial.
Figure 3. The impact of baseline left ventricular ejection fraction (LVEF)
on the development of heart failure after an myocardial infarction in the
CARE trial.
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tors of late development of HF in patients who survive the
initial high-risk months after MI and the impact of this late
HF development on mortality. The objective of this analysis
was to identify the factors predicting the development of
HF after MI among stable patients not previously treated
for HF.
The CARE population was a cohort of stable, long-term
survivors of acute MI, with 3,860 patients enrolled without
a previous history of HF. After a median follow-up of five
years, the cumulative incidence of HF was 6.3%, suggesting
that these patients remained at continued, albeit low, risk of
future adverse events such as HF, even though there was a
period of stability after the acute MI. The incidence of HF
increased linearly in a time-dependent fashion. This pattern
is consistent with the Framingham Heart Study population,
which experienced a 2% annual incidence of HF in survivors
of acute MI up to 10 years (14).
The cumulative incidence of HF in the CARE popula-
Table 2. Multivariate Predictors of Heart Failure Development and Heart Failure and Death in
Long-Term Survivors of MI
Variable
Heart Failure
Development
Heart Failure Development
and Death
HR 95% CI p Value HR 95% CI p Value
Age, increase 1 year 1.07 1.05–1.09  0.0001 1.06 1.05–1.07  0.001
LVEF, decrease by 1% 1.04 1.03–1.05  0.0001 1.03 1.02–1.04  0.001
Heart rate, increase by 4 beats/min 1.10 1.06–1.15  0.0001 1.06 1.03–1.10  0.001
History of hypertension 1.70 1.31–2.19  0.0001 1.34 1.12–1.62 0.0015
History of previous MI 1.75 1.32–2.33 0.0001 1.42 1.15–1.76 0.0013
Moderate exercise 0.67 0.52–0.86 0.0017 0.67 0.55–0.79  0.001
Diabetes 1.42 1.04–1.94 0.028 1.50 1.25–1.93 0.0003
Killip class at index MI (II) 1.36 0.97–1.92 0.078 1.36 1.06–1.73 0.0145
CI  confidence interval; HR  hazard ratio; LVEF  left ventricular ejection fraction; MI  myocardial infarction.
Figure 4. (A) The overall effect of the combination of age and left ventricular ejection fraction (LVEF) on the rate of hospitalizations for heart failure (HF)
over a mean follow-up of five years in the CARE population. (B) The overall effect of the combination of age and LVEF on the rate of hospitalizations
for HF and death over a mean follow-up of five years in the CARE population.
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tion was much lower than the incidence of acute HF
immediately after MI (16,17). The lower incidence of HF in
this population could be due to patient selection. Patients
with a previous history of HF were excluded and patients
had to survive for a minimum of three months after their
index MI to be eligible for this study. One reason for the
variation in the post-MI incidence of HF could be differing
mechanisms for the development of HF. Acute HF that
develops as an immediate consequence of acute MI may be
related to infarct characteristics such as the location and size
of the infarct and time to reperfusion (17–20). However,
late development of chronic HF among those without a
history of HF is probably related to several mechanisms,
including progressive remodeling (21,22), recurrent MI, and
subclinical ischemia.
The risk of most cardiac events such as HF is greatest in
the first few days post MI. Studies have demonstrated that
patients undergoing treatment for an initial MI have a 22%
incidence of acute HF before discharge, and the incidence
of HF in patients with recurrent MI is 33% (23,24). The
percentage of patients developing HF drops dramatically by
day 8 after acute MI (25). Because of the high incidence of
acute HF early after acute MI, the emphasis of previous
studies has been on the predictors and outcomes of HF
occurrence immediately following MI. Descriptive risk fac-
tors associated with early HF and an increased risk of death
post MI include older age, anterior location of MI, and
diabetes (25,26).
This study identified several factors that are important
predictors of HF development in long-term MI survivors
without a history of HF before the index MI. Independent
predictors of HF include four historical variables (age,
history of hypertension, history of MI before index MI, and
diabetes), one physical examination variable (heart rate), one
hemodynamic variable (ejection fraction), and one behav-
ioral characteristic (exercise level). Compared with the
Killip class at the time of the index MI, these seven factors
were more predictive of future HF events, suggesting that
clinical signs of HF at the time of the index MI may not be
as important in determining patients at high-risk of future
HF development. Some of these factors are similar to
predictors of acute HF immediately after an MI, such as age
and co-morbid illnesses (17,26). A lower LVEF may be a
reflection of a larger infarct, more extensive coronary artery
disease, less cardiac reserve, and poorer outcomes
(18,27,28). Although lower LVEF is a significant predictor,
only 14% of patients with LVEF 40% developed HF.
This is similar to the rate in the Survival And Ventricular
Enlargement (SAVE) trial population, in which only 15%
of patients with LVEF 40% required hospitalization for
HF (29). Interestingly, most patients who developed HF
did not experience another MI between the index event and
the development of HF, which supports the concept that a
chronic, time-dependent factor such as remodeling plays a
major role in this process. The low rate of recurrent MI in
this group could also explain the lack of effect of pravastatin
in preventing HF, a drug that decreases recurrent MI (9,30).
However, the impact of recurrent MI in increasing the risk
of HF development was dramatic and was observed in
patients at low, intermediate, or high risk of HF develop-
ment according to baseline predictors.
Patients who developed HF after surviving MI had a
markedly increased risk of death compared with patients
who did not develop HF, underscoring the importance of
HF development in this population. In the SAVE popula-
tion, the mortality risk was six fold greater over a 3.5-year
period in patients developing clinical HF requiring hospi-
talization than in patients with LVEF 40% but no clinical
HF (29). In the present study, the impact of HF develop-
ment on the risk of death in patients surviving a minimum
of three months after MI was more than 10-fold higher
than in patients not developing HF.
Study limitations. This study has several limitations. Be-
cause the development of HF in this study required hospi-
talization, less severe HF not requiring hospitalization was
not considered. Secondly, patients who died before devel-
Table 3. Description of the Risk Profiles Based on the Final Model
Risk Description
Heart Failure Heart Failure and Death
5-Year Rate HR (95% CI) 5-Year Rate HR (95% CI)
High risk
(n  341)
Age 60 years and LVEF 50% and diabetes
and hypertension
64 (18.8%) 15.1 (6.91–32.89) 105 (30.8%) 10.7 (6.34–18.17)
Intermediate risk
(n  3,048)
a) Age 55–60 years and LVEF 50% and
either diabetes or hypertension
172 (5.6%) 4.0 (1.88–8.52) 374 (12.3%) 3.8 (2.30–6.26)
b) Age 55–60 years and LVEF 50% and
diabetes and hypertension
c) Age 60 years and LVEF 50% and
diabetes and hypertension
d) Age 60 years and LVEF 50% and no
diabetes or hypertension
e) Age 60 years and LVEF 50% and
diabetes and hypertension
Low risk
(n  471)
Age 55 years and LVEF 50% and no
diabetes or hypertension
7 (1.5%) Reference 16 (3.4%) Reference
Abbreviations as in Table 2.
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oping HF were not included in this analysis. However,
because the final predictive model was also predictive of HF
and death, this limitation should not affect the validity of
the final model. Patients enrolled in a clinical trial are often
different from populations that are seen in the community,
which may be reflected in the relative high adherence rate to
regular exercise. Medications other than pravastatin were
used at the discretion of the treating physicians and there-
fore could not be included in the multivariable models.
Finally, CARE was not prospectively designed to assess the
risk factors for HF development post MI.
However, the results of this analysis have several impli-
cations in understanding the complex interaction between
MI and HF. Patients at continued risk of HF development
can be identified among long-term MI survivors, and in
these patients, often secondary prevention efforts should be
intensified. The understanding of the association of exercise
with HF development should be further studied to deter-
mine whether exercise is a marker of patients who are able
to exercise due to less severe disease or whether exercise
actually prevents HF development. The role of aggressive
therapy, such as revascularization, in improving outcomes
should be considered in patients with these risk factors for
the future development of HF. The efficacy of revascular-
ization in patients with a low ejection fraction and coronary
artery disease should partly be answered by the ongoing
Surgical Treatment for Ischemic Heart Failure (STICH)
trial. Because of the dramatic effect of HF on survival, as
well as the associated morbidity and cost after HF develop-
ment, there is an increasing need to understand potential
therapies that may decrease the late development of HF.
Conclusions. Long-term survivors of MI without a previ-
ous history of HF remain at risk of the development of HF.
A simple model consisting of baseline characteristics and
physiologic parameters can predict the late development of
HF. Moderate exercise at baseline independently decreases
the risk of HF development, even after adjusting for age and
co-morbid illnesses. Regardless of the baseline risk, recur-
rent MI dramatically impacts HF development, although it
was not a common occurrence. When HF occurs, the risk of
subsequent mortality is very high. The role of potential
interventions that may modify the risks of HF development
and mortality should be a focus of future investigations.
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